Previous 10 | Next 10 |
WILMINGTON, Del. , July 20, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) (the "Company"), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in ...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Our analysis concludes that if the sNDA filed by BioSpecifics Technologies' (BSTC) commercial partner, Endo International PLC (ENDP), for the use of BSTC's injectable collagenase ("CCH") in a product called XiaFlex to treat cellulite of the buttocks, is approved by the FDA as anticipated on Ju...
BioSpecifics Tech (NASDAQ: BSTC ): Q1 GAAP EPS of $0.61 misses by $0.15 . More news on: BioSpecifics Technologies Corp., Earnings news and commentary, Healthcare stocks news, Read more ...
WILIMINGTON, Del., May 11, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North A...
WILIMINGTON, Del., May 11, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North America , t...
WILMINGTON, Del. , April 10, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in North Am...
BioSpecifics Technologies (NASDAQ: BSTC ) has appointed Joseph Truitt as interim Chief Executive Officer (CEO). He will also serve on the Company's Board of Directors. More news on: BioSpecifics Technologies Corp., Healthcare stocks news, Read more ...
WILIMINGTON, Del., April 9, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX ® in North Ameri...
WILIMINGTON, Del., April 9, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America...
News, Short Squeeze, Breakout and More Instantly...
BioSpecifics Technologies Corp Company Name:
BSTC Stock Symbol:
NASDAQ Market:
BioSpecifics Technologies Corp Website:
Endo Announces Expiration Of Hart-Scott-Rodino Waiting Period For BioSpecifics Tender Offer PR Newswire DUBLIN, Nov. 18, 2020 DUBLIN , Nov. 18, 2020 /PRNewswire/ -- Endo International plc (Nasdaq: ENDP) (" Endo ") today announced the expiration of th...
New York, New York--(Newsfile Corp. - November 13, 2020) - Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether BioSpecifics Technologies Corp. (NASDAQ: BSTC) agreement to be acqui...
BioSpecifics Reports Third Quarter 2020 Financial and Operating Results - Endo acquisition of BioSpecifics expected to close in 4Q20 PR Newswire WILMINGTON, Del., Nov. 9, 2020 WILMINGTON, Del. , Nov. 9, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp....